# Phase 2 Urinary Bladder cancer trials recruiting: 57 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 57 trials in phase 2 for Urinary Bladder cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Urinary Bladder cancer trials: 57 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/urinary-bladder-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 57
- Recruiting or not yet: 57
- Read on: November 19, 2026

## Trials

The 25 newest of 57, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07908979 | Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer | Fox Chase Cancer Center | Phase 2 | Recruiting | Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908979) |
| September 30, 2026 | NCT07848854 | Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples | Yunnan Cancer Hospital | Phase 2 | Recruiting | Bladder Cancer (BC), Urothelial Carcinoma (UC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848854) |
| September 18, 2026 | NCT07827612 | A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer | Eli Lilly and Company | Phase 2 | Not yet recruiting | Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3 | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827612) |
| September 8, 2026 | NCT07808216 | Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT | Tianjin First Central Hospital | Phase 2 | Not yet recruiting | Non Muscle Invasive Bladder Cancer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808216) |
| August 28, 2026 | NCT07793318 | TR115 in ARID1A-Mutated Advanced Solid Tumors | Tarapeutics Science Inc. | Phase 2 | Not yet recruiting | Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793318) |
| August 13, 2026 | NCT07762586 | Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC) | Rutgers, The State University of New Jersey | Phase 2 | Recruiting | Bladder Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762586) |
| July 21, 2026 | NCT07717242 | Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Recruiting | Bladder Urothelial Carcinoma, Bladder Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717242) |
| July 8, 2026 | NCT07690878 | PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 | Not yet recruiting | Bladder Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690878) |
| June 23, 2026 | NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01) | Fudan University | Phase 2 | Not yet recruiting | Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662863) |
| June 11, 2026 | NCT07643519 | Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma | University of Florida | Phase 2 | Not yet recruiting | Urothelial Carcinoma (UC) | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643519) |
| June 10, 2026 | NCT07639983 | Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder Cancer | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639983) |
| March 16, 2026 | NCT07475403 | Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer | Tianjin Medical University Second Hospital | Phase 2 | Recruiting | Bladder Cancer, Liquid Biopsy, Immunotherapy | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07475403) |
| February 19, 2026 | NCT07420517 | Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Bladder Cancer | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07420517) |
| January 12, 2026 | NCT07332351 | Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder... | University of Washington | Phase 2 | Not yet recruiting | Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332351) |
| January 7, 2026 | NCT07322263 | Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC | Sponsor not shown (see the record) | Phase 2 | Recruiting | Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade... | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07322263) |
| December 29, 2025 | NCT07307456 | Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration | Changhai Hospital | Phase 2 | Recruiting | Bladder Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07307456) |
| December 16, 2025 | NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment... | Mayo Clinic | Phase 2 | Recruiting | Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285044) |
| December 2, 2025 | NCT07257718 | A Phase II, Prospective, Single-center Study of FAPI PET Imaging and Liquid Biopsy in Bladder Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Bladder Cancer | 262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07257718) |
| September 24, 2025 | NCT07189793 | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase... | First Affiliated Hospital of Wenzhou Medical University | Phase 2 | Not yet recruiting | Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder, Non-Muscle-Invasive Bladder... | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189793) |
| September 19, 2025 | NCT07184021 | Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer | Assiut University | Phase 2 | Not yet recruiting | Urinary Bladder Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07184021) |
| July 28, 2025 | NCT07087860 | Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers | Mayo Clinic | Phase 2 | Recruiting | Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07087860) |
| July 14, 2025 | NCT07061964 | Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07061964) |
| July 3, 2025 | NCT07050771 | Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery | The Methodist Hospital Research Institute | Phase 2 | Recruiting | Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa), Kidney Cancers, Bladder Cancer | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07050771) |
| May 21, 2025 | NCT06983210 | Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma | Nagoya University | Phase 2 | Recruiting | Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra... | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06983210) |
| May 7, 2025 | NCT06960577 | Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2) | AstraZeneca | Phase 2 | Recruiting | Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06960577) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 4 |
| Mayo Clinic | 2 |
| University of Florida | 2 |
| Rutgers, The State University of New Jersey | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| Yunnan Cancer Hospital | 1 |
| Roswell Park Cancer Institute | 1 |
| Tarapeutics Science Inc. | 1 |
| Zhujiang Hospital | 1 |
| National Cancer Center, Korea | 1 |
| Protara Therapeutics | 1 |
| Tianjin Medical University Second Hospital | 1 |
| University of Kansas Medical Center | 1 |
| University of Washington | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Northwestern University | 1 |
| University of California, Irvine | 1 |
| [Seagen, a wholly owned subsidiary of Pfizer](https://specstream.ai/data/clinical-trials/company/seagen-a-wholly-owned-subsidiary-of-pfizer) | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
| CG Oncology, Inc. | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Ankara University | 1 |
| Fore Biotherapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 30 |
| China | 13 |
| Canada | 10 |
| Italy | 7 |
| Spain | 7 |
| Japan | 6 |
| Australia | 6 |
| France | 6 |
| Netherlands | 5 |
| United Kingdom | 5 |
| South Korea | 4 |
| Argentina | 3 |
| Brazil | 3 |
| Germany | 3 |
| Taiwan | 2 |
| Belgium | 2 |
| Chile | 2 |
| Norway | 2 |
| Denmark | 2 |
| Hungary | 2 |
| Switzerland | 2 |
| Ukraine | 1 |
| Puerto Rico | 1 |
| Israel | 1 |
| Turkey (Türkiye) | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Arabian restaurants in the United States](https://specstream.ai/data/businesses/arabian-restaurants/united-states)
- [Otology practices in the United States](https://specstream.ai/data/businesses/otology-practices/united-states)
- [Drive thru bars in the United States](https://specstream.ai/data/businesses/drive-thru-bars/united-states)
- [Trinidadian restaurants in the United States](https://specstream.ai/data/businesses/trinidadian-restaurants/united-states)
- [Law firms in the United States](https://specstream.ai/data/businesses/law-firms/united-states)
- [Career counseling services in the United States](https://specstream.ai/data/businesses/career-counseling-services/united-states)
